🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
154.68
-1.91 (-1.22%)
Nov 20, 2026, 10:20 AM EST - Market open

Neurocrine Biosciences Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
702.5478.6341.3249.7154.589.6
Depreciation & Amortization
83.630.127.121.315.610.9
Other Amortization
-----17.3
Loss (Gain) From Sale of Assets
-28.6-----
Asset Writedown & Restructuring Costs
0.70.714---
Loss (Gain) From Sale of Investments
24.8-8.710.9-46.7-27.1-13.5
Stock-Based Compensation
235.1217.9195.5194.3173.1134.2
Other Operating Activities
-8.3192.925.8-56.990.71.3
Change in Accounts Receivable
-197.5-210.5-39.8-89.3-162.2-28.4
Change in Inventory
-2.3-15.3-19.15.4-2.6-2.5
Change in Accounts Payable
130.5160.243.449114.656.8
Change in Income Taxes
139.1-18.850.391.6--
Change in Other Net Operating Assets
-13.8-44.4-54-28.5-17.2-9.2
Operating Cash Flow
1,066782.7595.4389.9339.4256.5
Operating Cash Flow Growth
67.37%31.46%52.71%14.88%32.32%12.25%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-26.1-34-38.2-28.3-16.5-23.4
Cash Acquisitions
-2,359----42.7-
Investment in Securities
1,616-230.4-88.6-438.8-117.9-106.8
Investing Cash Flow
-705.6-264.4-126.8-467.1-177.1-130.2

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Repaid
---308.8--279-0.1
Net Debt Issued (Repaid)
---308.8--279-0.1
Issuance of Common Stock
171129.4122.165.344.727.5
Repurchase of Common Stock
-224.7-167.7-300---
Financing Cash Flow
-60.4-38.3-486.765.3-234.327.4

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
---0.3-1.3-
Net Cash Flow
299.8480-18.1-11.6-73.3153.7

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,040748.7557.2361.6322.9233.1
Free Cash Flow Growth
75.30%34.37%54.09%11.98%38.52%7.12%
Free Cash Flow Margin
28.09%26.17%23.66%19.16%21.69%20.57%
Free Cash Flow Per Share
9.987.305.373.583.272.38
Levered Free Cash Flow
1,018397.81507.33439.25247.63265.75
Unlevered Free Cash Flow
1,020397.81507.33439.25247.63264.58

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
2.7-1.63.86.68.6
Cash Income Tax Paid
119.181.4217.551.514.45.1
Change in Working Capital
56-128.8-19.228.2-67.416.7
SEC Filings: 10-K · 10-Q